SCHEMBL2899494

SCHEMBL2899494

C=CCC(NC(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 2/20 0.50
MAPT P10636 1/20 0.50
ALOX15 P16050 1/20 0.50
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629199 0.86 CYP2C19 (0.53) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL253718 0.84 ALDH1A1 (0.42) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL1273278 0.84 ALDH1A1 (0.42) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL16972136 0.83 ALDH1A1 (0.43) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL18425130 0.83 ALDH1A1 (0.43) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL27189897 0.82 HSD17B10 (0.54) CYP2C19SMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL17845998 0.80 CYP2C19 (0.42) CYP2C19SMN1; SMN2ALDH1A1HTTNCOA1
SCHEMBL21268612 0.79 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1KDM4EHSD17B10HTT
SCHEMBL115980 0.79 ROCK1 (0.55)
SCHEMBL4598191 0.79 ROCK1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814537-B1 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-11-12 EP disclosed
US-7678783-B2 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2010-03-16 US disclosed
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 CYP2C19 1307/4885SMN1; SMN2 1326/4885ALDH1A1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.